Ravulizumab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 455 publications
Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.
Journal: Current medical research and opinion
Published: July 24, 2026
Atypical Hemolytic Uremic Syndrome Associated With Malignant Hypertension Presenting With Pulmonary-Renal Syndrome-like Symptoms.
Journal: Kidney medicine
Published: July 19, 2026
Current practices in antibiotic prophylaxis for patients on complement inhibitors: a multicenter survey across ERN ERKnet centers.
Journal: Clinical kidney journal
Published: July 14, 2026
Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: July 13, 2026
Complement System Inhibitors in Nephrology: A Comprehensive Review.
Journal: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
Published: July 09, 2026
Inebilizumab (Uplizna) for myasthenia gravis.
Journal: The Medical letter on drugs and therapeutics
Published: June 25, 2026
Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case report.
Journal: Internal medicine (Tokyo, Japan)
Published: June 10, 2026
Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort study.
Journal: Journal of critical care
Published: June 04, 2026
A decade of complement inhibition in post-transplant atypical HUS: outcomes with eculizumab and ravulizumab.
Journal: Clinical kidney journal
Published: May 30, 2026
Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.
Journal: Expert review of clinical pharmacology
Published: May 29, 2026
Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: May 25, 2026
Last Updated: 09/26/2026